DOCSLIB.ORG

WHO Drug Information Vol. 03, No. 4, 1989

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WHO Drug Information Vol. 03, No. 4, 1989 WHO DRUG INFORMATION VOLUME 3 • NUMBER 4 • 1989 PROPOSED INN LIST 62 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA WHO Drug Information WHO Drug Information provides an cerned with the rational use of overview of topics relating to drug drugs. In effect, the journal seeks development and regulation that to relate regulatory activity to are of current relevance and im­ therapeutic practice. It also aims to portance, and will include the lists provide an open forum for debate. of proposed and recommended In­ Invited contributions will portray a ternational Nonproprietary Names variety of viewpoints on matters of for Pharmaceutical Substances general policy with the aim of (INN). Its contents reflect, but do stimulating discussion not only not present, WHO policies and ac­ in these columns but wherever tivities and they embrace socio­ relevant decisions on this subject economic as well as technical mat­ have to be taken. ters. WHO Drug Information is pub­ The objective is to bring issues that lished 4 times a year in English and are of primary concern to drug French. regulators and pharmaceutical manufacturers to the attention of a Annual subscription: Sw.fr. 50.— wide audience of health profes­ Airmail rate: Sw.fr. 60.— sionals and policy-makers con­ Price per copy: Sw.fr. 15.— © World Health Organization 1989 Authors alone are responsible for views expressed Publications of the World Health Organization in signed contributions. enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal The mention of specific companies or of certain Copyright Convention. For rights of reproduc­ manufacturers' products does not imply that they are tion or translation, in part or In toto, applica­ endorsed or recommended by the World Health tion should be made to: Chief, Office of Organization in preference to others of a similar na­ Publications, World Health Organization, ture which are not mentioned. Errors and omissions 1211 Geneva 27, Switzerland. The World excepted, the names of proprietary products are Health Organization welcomes such applica­ distinguished by initial capital letters. tions. The designations employed and the presen­ tation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concern­ ing the delimitation of its frontiers or boun­ daries. ISSN 1010-9609 WHO Drug Information Vol. 3, No. 4, 1989 World Health Organization, Geneva WHO Drug Information Contents General Policy Topics Ethylene oxide: a potential carcinogen? 183 Hair restorers on prescription only 184 Reserve antibiotics 165 Mefloquine: restrictive labelling 184 Metamizole: withdrawal of combination Personal Perspectives products 184 Counterfeit medicines: a problem Sulfonamides: suppository formulations of today 167 withdrawn 185 L-Tryptophan supplements Reports on Individual Drugs and eosinophilia-myalgia syndrome 185 Vasodilator therapy following myocardial infarction 169 Advisory Notices Praziquantel: are there brand differences? 169 Delayed shock and low osmolar Progestational contraceptives: radiocontrast media 186 also a risk factor for breast cancer? 170 Counterfeit dermatological products 186 Plasma substitutes and renal failure 171 Counterfeit Fansidar® 186 Haemopoietic growth factors as Flunarizine and extrapyramidal symptoms 186 adjuvants in cancer chemotherapy 171 Minoxidil and contact dermatitis 186 Haemophilia: the therapeutic dilemma 172 Retinoids and necrotizing vasculitis 187 Calcium channel blockers: a need Steroid aerosols and cataract 187 for reassessment? 173 Oral contraceptives and older women 188 Antimalarials and pruritus 174 Xamoterol: inappropriate for severe heart failure 188 General Information Zidovudine: carcinogenic potential 188 Should antimalarials be given to all Zidovudine-induced neutropenia 188 pregnant women at risk? 175 Cost-effective health care delivery 176 Cost-conscious prescribing 176 Essential Drugs Hazards of herbal medicines 177 WHO Model List: Sixth Revision 191 Generic drug products: is interchangeability still an issue? 178 204 Drugs in donated blood 179 Newly Registered Products Adverse reaction reporting: engaging commitment 179 DNA probes: a new generation Recent Publications of diagnostic tools 180 The role and function of the pharmacist How often are drugs really taken? 181 in Europe 205 Asthma: inadequacies in concepts Clandestinely produced drugs, and management 181 analogues and precursors 205 Naming organic compounds 205 Regulatory Matters The business of pharmaceutical inspection 206 Aminoglycoside antibiotics: restrictive measures 183 Aphrodisiac activity: no more claims 183 Proposed International Non­ Cosmetics: disclosure of ingredients 183 proprietary Names: List 62 207 i WHO Drug Information Vol. 3, No. 4, 1989 General Policy Topics Reserve antibiotics with the emergence of multiresistant staphylococci Few would contest that antibiotics have contributed (many of which are now sensitive only to vanco­ more to the advancement of medical care over the mycin), has shown that the evolution of resistance past half-century than virtually any other class of constantly threatens to outstrip innovative capacity. therapeutic substances. Where they are readily available and effectively used, bacterial disease Great harm has similarly resulted, to quote but one has long ceded its former dominance as a primary further example, from widespread incursions of cause of mortality. But there are no grounds for resistant beta-lactamase-producing strains of complacency because pathogenic bacteria are Haemophilus influenzae (7) and gonococci (8). Now constantly posing new therapeutic challenges. fears are being expressed that multiresistant strains Earlier editions of institutional and national formu­ of such major and ubiquitous pathogens as laries provide a salutory reminder that, twenty years Streptococcus pyogenes (9) and Streptococcus ago, all but the most exceptional needs were pneumoniae (10) threaten to become more widely satisfied by 20 to 30 substances. Today, the same distributed. As yet, there is no means of determin­ handbooks list at least three times as many. Costs ing the likely extent of such trends since they follow are also escalating: it is claimed that, in many no established pattern. health-care settings, antibiotics now account for 15 to 30 per cent of the total drug budget (1). What is certain is that these and many other manifestations of resistance are genetically In some measure, these developments are forced determined and that the diverse cytoplasmic by the degree to which the effectiveness of long- transposons and plasmids that carry many of the established, relatively cheap antibiotics has been responsible genes sometimes migrate to other eroded by resistant strains of pathogenic bacteria strains and species of bacteria (3). The potential for (2, 3). It is inevitable that any use of antibiotics will transfer of one, or even of several genes encoding tend to generate selection pressure favouring the for specific mechanisms of resistance is conse­ emergence of resistant strains. However, this quently limitless and largely unpredictable. Inevita­ pressure has been intensified, gratuitously and bly, the outcome is that the resulting emergence of sometimes recklessly, firstly, by the prodigious resistance often makes the cheaper, long-estab­ scale on which these substances are now used — lished antibiotics unreliable for use in serious not only within medicine but in livestock farming (4) infections. — and, secondly, by irrational prescribing practices often inspired by the promotion of broad spectrum This reality has led a WHO Expert Committee, antibiotics as panaceas which dispose of the need meeting in Geneva in December 1989, to consider for diagnostic precision (5, 6). how the situation might best be reflected in the latest biennial revision of the Model List of Essential Too often in the past such complacency has been Drugs (set out on page 191 of this issue). It has fuelled by expectation that the pharmaceutical decided that the concept and purpose of the List industry can be confidently relied upon to produce would be unacceptably compromised simply by yet another generation of effective and safe incorporating into it a range of relatively new and substances to replace those compromised by resis­ expensive antibiotics. Instead, it proposed the con­ tance, and that the prevalence of resistant strains cept of "reserve antibiotics" — substances which can, in any case, be reduced simply by adjusting are useful for a wide range of infections, but which prevailing prescribing policies to relieve the are inappropriate for unrestricted use because of selection pressure. Neither of these assumptions is the need to reduce the risk of development of resis­ warranted. The performance of the research-based tance to them and because of their relatively high pharmaceutical industry in the innovation of cost. It identified the third generation cefalosporins, antibiotics has, indeed, been spectacular. However, the quinolones, and vancomycin as being illustra­ experience over the past two decades, particularly tive of such products in the following situations: 165 General Policy Topics WHO Drug Information Vol. 3, No. 4, 1989 "Several third generation cefalosporins are suitable ment and use of antibiotics everywhere and
Load more

Recommended publications
  • Inflammatory Bowel Disease Irritable Bowel Syndrome
    Inflammatory Bowel Disease and Irritable Bowel Syndrome Similarities and Differences 2 www.ccfa.org IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 Important Differences Between IBD and IBS Many diseases and conditions can affect the gastrointestinal (GI) tract, which is part of the digestive system and includes the esophagus, stomach, small intestine and large intestine. These diseases and conditions include inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 www.ccfa.org 3 Inflammatory bowel diseases are a group of inflammatory conditions in which the body’s own immune system attacks parts of the digestive system. Inflammatory Bowel Disease Inflammatory bowel diseases are a group of inflamma- Causes tory conditions in which the body’s own immune system attacks parts of the digestive system. The two most com- The exact cause of IBD remains unknown. Researchers mon inflammatory bowel diseases are Crohn’s disease believe that a combination of four factors lead to IBD: a (CD) and ulcerative colitis (UC). IBD affects as many as 1.4 genetic component, an environmental trigger, an imbal- million Americans, most of whom are diagnosed before ance of intestinal bacteria and an inappropriate reaction age 35. There is no cure for IBD but there are treatments to from the immune system. Immune cells normally protect reduce and control the symptoms of the disease. the body from infection, but in people with IBD, the immune system mistakes harmless substances in the CD and UC cause chronic inflammation of the GI tract. CD intestine for foreign substances and launches an attack, can affect any part of the GI tract, but frequently affects the resulting in inflammation.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • Updates in Pediatric Dermatology
    Peds Derm Updates ELIZABETH ( LISA) SWANSON , M D ADVANCED DERMATOLOGY COLORADO ROCKY MOUNTAIN HOSPITAL FOR CHILDREN [email protected] Disclosures Speaker Sanofi Regeneron Amgen Almirall Pfizer Advisory Board Janssen Powerpoints are the peacocks of the business world; all show, no meat. — Dwight Schrute, The Office What’s New In Atopic Dermatitis? Impact of Atopic Dermatitis Eczema causes stress, sleeplessness, discomfort and worry for the entire family Treating one patient with eczema is an example of “trickle down” healthcare Patients with eczema have increased risk of: ADHD Anxiety and Depression Suicidal Ideation Parental depression Osteoporosis and osteopenia (due to steroids, decreased exercise, and chronic inflammation) Impact of Atopic Dermatitis Sleep disturbances are a really big deal Parents of kids with atopic dermatitis lose an average of 1-1.5 hours of sleep a night Even when they sleep, kids with atopic dermatitis don’t get good sleep Don’t enter REM as much or as long Growth hormone is secreted in REM (JAAD Feb 2018) Atopic Dermatitis and Food Allergies Growing evidence that food allergies might actually be caused by atopic dermatitis Impaired barrier allows food proteins to abnormally enter the body and stimulate allergy Avoiding foods can be harmful Proper nutrition is important Avoidance now linked to increased risk for allergy and anaphylaxis Refer severe eczema patients to Allergist before 4-6 mos of age to talk about food introduction Pathogenesis of Atopic Dermatitis Skin barrier
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • UNIVERSITE DE NANTES Thomas Gelineau
    UNIVERSITE DE NANTES __________ FACULTE DE MEDECINE __________ Année 2011 N° 139 THESE pour le DIPLÔME D’ÉTAT DE DOCTEUR EN MÉDECINE DES de médecine générale par Thomas Gelineau né le 29 janvier 1983 à Cholet __________ Présentée et soutenue publiquement le 06/12/2011 __________ LE RHUME DE L'ENFANT ET SON TRAITEMENT: DECISION PARTAGEE AVEC LES PARENTS D'APRES UN QUESTIONNAIRE __________ Président : Monsieur le Professeur Olivier MALARD Directeur de thèse : Madame le Professeur Jacqueline LACAILLE 1 Table des matières IIntroduction................................................................................................................ 7 IIDéfinition, état des connaissances...........................................................................8 1Le rhume.......................................................................................................................................8 APhysiopathologie............................................................................................................................. 8 aL'origine virale.................................................................................................................................... 8 bLa saisonnalité................................................................................................................................... 8 cL'âge de survenue.............................................................................................................................. 9 dLe sexe..................................................................................................................................................
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • EAR, NOSE and OROPHARYNX Updated: October 2020
    Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY CHAPTER 12: EAR, NOSE AND OROPHARYNX Updated: October 2020 The following prescribing guidelines are relevant to the ENT chapter and can be found here: • Allergic Rhinitis in adults and adolescents over 12 years of age • Management of chronic rhinosinusitis with or without nasal polyps 12.1 DRUGS ACTING ON THE EAR 12.1.1 Otitis externa Investigation is not routinely recommended for the initial diagnosis of otitis externa. Group Drug Astringent/acidic Acetic acid 2% ear spray preparations Self-care: patients are advised to purchase this over the counter Gentamicin 0.3% ear/eye drops* Antibiotic preparations Ciprofloxacin 2mg/ml ear drops 0.25ml unit dose PF Betnesol-N ear/eye/ nose drops* Combined corticosteroid (Betamethasone 0.1% & neomycin 0.5%) and aminoglycoside Otomize ear spray* antibiotic preparations (Dexamethasone 0.1%, neomycin 0.5% & acetic acid 2%) Corticosteroid Prednisolone 0.5% ear/eye drops Lower potency preparations Betamethasone 0.1% ear/eye/ nose drops Higher potency Antifungal preparations Clotrimazole 1% solution 20ml (with dropper) * In view of reports of ototoxicity, manufacturers contra-indicate treatment with topical aminoglycosides in patients with a perforated tympanic membrane (eardrum) or patent grommet. 1. The following are GREY, not for first line empirical use, and should only be used when sensitivity is confirmed through swab results- • Hydrocortisone acetate 1%/gentamicin 0.3% ear drops • Flumetasone pivalate 0.02%/clioquinol 1% ear drops 2. How should I treat acute diffuse otitis externa? (CKS) • Remove or treat any precipitating or aggravating factors. • Prescribe or recommend a simple analgesic for symptomatic relief.
    [Show full text]
  • Chemical Ligand Space of Cereblon Iuliia Boichenko,† Kerstin Bar,̈ Silvia Deiss, Christopher Heim, Reinhard Albrecht, Andrei N
    This is an open access article published under a Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. Article Cite This: ACS Omega 2018, 3, 11163−11171 http://pubs.acs.org/journal/acsodf Chemical Ligand Space of Cereblon Iuliia Boichenko,† Kerstin Bar,̈ Silvia Deiss, Christopher Heim, Reinhard Albrecht, Andrei N. Lupas, Birte Hernandez Alvarez,* and Marcus D. Hartmann* Department of Protein Evolution, Max Planck Institute for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany *S Supporting Information ABSTRACT: The protein cereblon serves as a substrate receptor of a ubiquitin ligase complex that can be tuned toward different target proteins by cereblon-binding agents. This approach to targeted protein degradation is exploited in different clinical settings and has sparked the development of a growing number of thalidomide derivatives. Here, we probe the chemical space of cereblon binding beyond such derivatives and work out a simple set of chemical requirements, delineating the metaclass of cereblon effectors. We report co-crystal structures for a diverse set of compounds, including commonly used pharmaceuticals, but also find that already minimalistic cereblon-binding moieties might exert teratogenic effects in zebrafish. Our results may guide the design of a post-thalidomide generation of therapeutic cereblon effectors and provide a framework for the circumvention of unintended cereblon binding by negative design
    [Show full text]
  • Ep 1553091 A1
    Europäisches Patentamt *EP001553091A1* (19) European Patent Office Office européen des brevets (11) EP 1 553 091 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: C07D 263/32, C07D 417/14, 13.07.2005 Bulletin 2005/28 C07D 333/20, C07D 413/12, C07D 417/06 (21) Application number: 04726765.3 (86) International application number: (22) Date of filing: 09.04.2004 PCT/JP2004/005119 (87) International publication number: WO 2004/089918 (21.10.2004 Gazette 2004/43) (84) Designated Contracting States: • SAKAMOTO, Johei AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Takatsuki-shi, Osaka 569-1125 (JP) HU IE IT LI LU MC NL PL PT RO SE SI SK TR • NAKANISHI, Hiroyuki Designated Extension States: Takatsuki-shi, Osaka 569-1125 (JP) AL HR LT LV MK • NAKAGAWA, Yuichi Takatsuki-shi, Osaka 569-1125 (JP) (30) Priority: 09.04.2003 JP 2003105267 • OHTA, Takeshi 03.06.2003 JP 2003157590 Takatsuki-shi, Osaka 569-1125 (JP) • SAKATA, Shohei (71) Applicant: Japan Tobacco Inc. Takatsuki-shi, Osaka 569-1125 (JP) Tokyo 105-8422 (JP) • MORINAGA, Hisayo Takatsuki-shi, Osaka 569-1125 (JP) (72) Inventors: • IKEMOTO, Tomoyuki (74) Representative: Takatsuki-shi, Osaka 569-1125 (JP) von Kreisler, Alek, Dipl.-Chem. et al • TANAKA, Masahiro Deichmannhaus am Dom, Takatsuki-shi, Osaka 569-1125 (JP) Postfach 10 22 41 • YUNO, Takeo 50462 Köln (DE) Takatsuki-shi, Osaka 569-1125 (JP) (54) HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF (57) A 5-membered heteroaromatic ring compound represented by the formula [I] 1 2 4 5 7 wherein V is CH or N; W is S or O; R and R are each H etc.; X is -N(R )-, -O-, -S-, -SO2-N(R )-, -CO-N(R )- etc.; L is EP 1 553 091 A1 Printed by Jouve, 75001 PARIS (FR) (Cont.
    [Show full text]
  • Sulfasalazine (Azulfidine)
    Sulfasalazine (Azulfidine) Description Sulfasalazine (Azulfidine), used to treat pain and swelling in arthritis, belongs to a class of drugs called sulfa drugs. It is a combination of salicylate (the main ingredient in aspirin) and a sulfa antibiotic. Sulfasalazine is also known as a disease modifying antirheumatic drug (DMARD) because it not only decreases the pain and swelling of arthritis, but also may prevent damage to joints. In addition, it may reduce the risk of long term loss of function. Uses Sulfasalazine was first used over 70 years ago to treat rheumatoid arthritis which, at one time, was thought to be caused by a bacterial infection. Sulfasalazine was designed as a combination of an aspirin- like anti-inflammatory medicine with a sulfa containing antibiotic. While a bacterial infectious cause for rheumatoid arthritis is longer believed to be true, sulfasalazine continues to be useful for treating for mild to moderate symptoms, or may be given with other drugs for more severe symptoms of rheumatoid arthritis. It is also used for other conditions, including juvenile idiopathic arthritis (also called juvenile rheumatoid arthritis), ankylosing spondylitis, psoriatic arthritis, and ulcerative colitis. How it works Sulfasalazine treats swelling, pain, and stiffness in arthritis. However, it is not entirely clear how this medication works for rheumatoid arthritis. Dosing Sulfasalazine comes in a 500 milligram tablet, and should be taken with food and a full glass of water to prevent stomach upset. The medication is often started at low doses to treat rheumatoid arthritis, typically one to two tablets a day, to prevent side effects. After the first week, the dose may be increased slowly to the usual 2 tablets (1 gram) taken twice a day.
    [Show full text]